Prevest Denpro Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹452 Cr
- P/E
- 20.03
- ROE
- 18.51%
- PEG
- 1.83
- Price to sales
- 6.00
- Debt to equity
- 0.00
- 52W high / low
- ₹533 / ₹342
- Sales growth (5Y)
- 20.33%
- EBITDA margin
- 35.69%
- Net profit margin
- 29.89%
- Promoter holding
- 73.60%
- Sales (last year)
- ₹75 Cr
Incorporated in 2000, Prevest DenPro Limited is into development and manufacturing of dental materials used for diagnosis, prevention and treatment of dental conditions. Company is heavily export-oriented.
Guidance scorecard · Q1 FY27 call
What Prevest Denpro Ltd's management guided
and where it ranks in Healthcare Equipment & Supplies
Healthcare Equipment & Supplies
RevenueQ1 FY27 call
10–20%- The US business is expected to grow significantly over the next 2-3 years, driven by private labeling and online sales, with aggressive participation in US exhibitions.
- Digital dentistry revenue, especially 3D printing resins, grew 40% this year; 3D printer sales rose by 162%, indicating strong growth potential, with plans for an indigenous 3D printer by 2028.
- Export markets are expected to expand with new international market entries and subsidiaries in the USA and UAE contributing to growth.
- Domestic sales are projected to increase through expanded distribution in Tier 2 and Tier 3 cities and enhancing sales team strength.
- New product launches in the Oradox oral health segment and disinfectants business anticipate boosting revenues.
2 more points from Prevest Denpro Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
FlatSee what Prevest Denpro Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- Prevest DenPro is actively investing in the development of a fully indigenous 3D printer, targeting commercialization by 2028, enhancing their digital dentistry portfolio.
- The company is expanding its disinfectant business vertical, with plans to invest in broadening its product portfolio in a disciplined, phased manner over the coming years.
- Continuous investment is being made in advanced digital solutions and research and development to strengthen leadership in digital dentistry.
- The company is working on import substitution for key raw materials, reducing dependency on foreign suppliers, which is part of their capital and R&D efforts.
2 more points from Prevest Denpro Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
See what Prevest Denpro Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
- The company is experiencing strong demand growth, especially in the US and digital dentistry segments.
- OEM business is expanding, with 3-4 big companies currently being served and plans to add 2 more in the next 2 years.
- Participation in multiple exhibitions in the USA and Dubai is generating new orders, particularly in private labeling and online sales.
- Despite geopolitical challenges, the order pipeline remains resilient with growth prospects.
2 more points from Prevest Denpro Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Equipment & Supplies
on management's own guidance
- Strong growth2
- Strong growth1
- Q-Line BiotechGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Healthcare Equipment & Supplies companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Flat | ₹627 Cr | 21.4 | |
| 2 | 40%+ | Flat | ₹147 Cr | 16.8 | |
| 3 | Q-Line Biotech | 20–40% | Up 2%+ | ₹1,467 Cr | 25.9 |
| 4 | 20–40% | Flat | ₹18,144 Cr | 83.6 | |
| 5 | 20–40% | Flat | ₹173 Cr | 35.0 | |
| 6 | 10–20% | Up 2%+ | ₹170 Cr | 18.8 |
Sign up free to see every company in the sector ranking and track Prevest Denpro Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Healthcare Equipment & Supplies rankingFinancials of Prevest Denpro Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Prevest Denpro Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 13.77 | 13.39 | 13.18 | 13.62 | 16.24 | 13.34 | 16.26 | 14.93 | 18.54 | 15.72 | 18.66 | 18.37 | 18.90 |
| Expenses + | 8.16 | 8.43 | 8.68 | 9.15 | 10.36 | 8.85 | 10.45 | 9.79 | 11.91 | 10.19 | 11.96 | 12.15 | 11.81 |
| Operating Profit | 5.61 | 4.96 | 4.50 | 4.47 | 5.88 | 4.49 | 5.81 | 5.14 | 6.63 | 5.53 | 6.70 | 6.22 | 7.09 |
| OPM % | 40.74% | 37.04% | 34.14% | 32.82% | 36.21% | 33.66% | 35.73% | 34.43% | 35.76% | 35.18% | 35.91% | 33.86% | 37.51% |
| Other Income + | 0.33 | 0.61 | 0.74 | 0.68 | 0.84 | 0.86 | 1.07 | 1.10 | 1.08 | 1.17 | 1.20 | 1.16 | 1.46 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.16 | 0.17 | 0.22 | 0.42 | 0.46 | 0.48 | 0.47 | 0.48 | 0.47 | 0.49 | 0.50 | 0.51 | 0.50 |
| Profit before tax | 5.78 | 5.40 | 5.02 | 4.73 | 6.26 | 4.87 | 6.41 | 5.76 | 7.24 | 6.21 | 7.40 | 6.87 | 8.05 |
| Tax % | 11.76% | 24.26% | 25.70% | 23.26% | 25.56% | 25.26% | 24.49% | 22.40% | 27.49% | 25.44% | 24.73% | 25.04% | 24.72% |
| Net Profit + | 5.11 | 4.08 | 3.74 | 3.64 | 4.66 | 3.65 | 4.84 | 4.46 | 5.25 | 4.63 | 5.57 | 5.15 | 6.06 |
| EPS in Rs | 4.26 | 3.40 | 3.12 | 3.03 | 3.88 | 3.04 | 4.03 | 3.72 | 4.37 | 3.86 | 4.64 | 4.29 | 5.05 |
Financials of Prevest Denpro Ltd
Profit & Loss
Annual income statement trend
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 19 | 23 | 28 | 38 | 50 | 56 | 63 | 72 |
| Expenses + | 15 | 17 | 19 | 23 | 30 | 36 | 41 | 46 |
| Operating Profit | 4 | 5 | 9 | 15 | 20 | 20 | 22 | 26 |
| OPM % | 20% | 23% | 32% | 40% | 40% | 36% | 35% | 36% |
| Other Income + | 0 | 2 | 1 | 2 | 2 | 3 | 4 | 5 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 2 |
| Profit before tax | 4 | 6 | 9 | 16 | 21 | 21 | 24 | 29 |
| Tax % | 20% | 20% | 23% | 28% | 25% | 25% | 25% | 25% |
| Net Profit + | 3 | 5 | 7 | 12 | 16 | 16 | 18 | 21 |
| EPS in Rs | 1,049.12 | 1,757.89 | 252.98 | 9.64 | 13.09 | 13.43 | 15.16 | 17.85 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 8% | 7% | 7% | 0% |
Financials of Prevest Denpro Ltd
Balance Sheet
Capital structure and asset base
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.29 | 0.29 | 0.29 | 12 | 12 | 12 | 12 | 12 |
| Reserves | 10 | 15 | 22 | 45 | 61 | 77 | 94 | 114 |
| Borrowings + | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 0 |
| Other Liabilities + | 4 | 4 | 7 | 6 | 6 | 6 | 7 | 8 |
| Total Liabilities | 15 | 21 | 31 | 64 | 79 | 95 | 113 | 134 |
| Fixed Assets + | 5 | 5 | 5 | 7 | 7 | 27 | 27 | 27 |
| CWIP | 0 | 0 | 2 | 5 | 17 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 1 | 1 | 2 | 5 | 9 |
| Other Assets + | 10 | 16 | 23 | 52 | 53 | 66 | 81 | 98 |
| Total Assets | 15 | 21 | 31 | 64 | 79 | 95 | 113 | 134 |
Financials of Prevest Denpro Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 3 | 5 | 9 | 7 | 10 | 11 | 15 | |
| Cash from Investing Activity + | -1 | -1 | -2 | -4 | -12 | -2 | -2 | |
| Cash from Financing Activity + | 0 | 0 | -1 | 23 | -1 | -0 | -1 | |
| Net Cash Flow | 2 | 4 | 6 | 26 | -3 | 9 | 12 | |
| Free Cash Flow | 2 | 4 | 7 | 2 | -3 | 8 | 13 | |
| CFO/OP | 96% | 115% | 118% | 75% | 79% | 80% | 94% |
Financials of Prevest Denpro Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 46 | 35 | 48 | 22 | 31 | 53 | 45 | 45 |
| Inventory Days | 28 | 59 | 59 | 122 | 139 | 162 | 208 | 235 |
| Days Payable | 70 | 72 | 181 | 61 | 40 | 34 | 42 | 53 |
| Cash Conversion Cycle | 4 | 22 | -74 | 83 | 130 | 181 | 211 | 227 |
| Working Capital Days | 10 | 20 | 3 | 41 | 64 | 80 | 82 | 134 |
| ROCE % | 45% | 47% | 40% | 32% | 27% | 25% | 25% |
Guidance history
How Prevest Denpro Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 10–20% | Flat | Planned | — | — |
| Q2 FY26 call → | 20–40% | Flat | None planned | — | Rising |
| Q4 FY25 call → | 10–20% | Flat | Planned | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Continue your research
What Prevest Denpro Ltd's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Galaxy Medicare (Q2 FY27)
Revenue from Operations (₹ Mn): . Key investor presentation takeaways from Galaxy Medicare's Q2 FY27 investor presentation — and how it ranks against sector pee
- Nureca Ltd (Q2 FY27)
Year-on-year growth in revenue from operations: approximately 55% increase (585.99 vs 378.41 million standalone) . Key results statement takeaways from Nureca's
- Aprameya Engineering Ltd (Q2 FY26)
H1FY26 Revenue from Operations: Rs 421.4 Mn, up 343% YoY from Rs 92.7 Mn in H1FY25. Key investor presentation takeaways from Aprameya Engineering Ltd's Q2 FY26
- Nureca Ltd (Q2 FY26)
Q2 FY26 Revenue from Operations: INR 528 million, a 7% year-on-year (YoY) growth from INR 493 million in Q2 FY25. Key investor presentation takeaways from Nurec